<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="disease 2019 (COVID-19) pandemic has quickly intensified interest in developing" exact="treatment" post="options to mitigate impact on human life. Remdesivir (GS-5734â&quot;¢)"/>
 <result pre="antiviral drug that is now being tested as a potential" exact="treatment" post="for COVID-19 in international, multi-site clinical trials. Currently available"/>
 <result pre="2012 and November 2019, there were 2494 laboratory-confirmed cases of" exact="infection" post="with Middle East respiratory syndrome coronavirus (MERS-CoV) that reached"/>
 <result pre="approximately 34% [4], though serologic studies have implied that the" exact="prevalence" post="of MERS-CoV may have been underestimated [5]. Most recently,"/>
 <result pre="the world has generated intense interest in vaccine development and" exact="treatment" post="options for coronavirus disease 2019 (COVID-19) [6,7]. Remdesivir (GS-5734,"/>
 <result pre="[9], [10], [11], [12]]. Originally developed to treat Ebola virus" exact="infection" post="[8], remdesivir is a prodrug of the parent adenosine"/>
 <result pre="[50]. There are currently no antiviral drugs approved for the" exact="treatment" post="of CoV-specific illnesses. Given the rapidly evolving pandemic of"/>
 <result pre="impact of seven different drugs on viral titers, cytotoxicity, and" exact="infection" post="rates, using Vero E6 cells (a cell line originating"/>
 <result pre="more plaque-forming units), those receiving prophylactic remdesivir one day before" exact="infection" post="had significantly better 6-day survival than infected control mice"/>
 <result pre="Ces1c-knockout mouse model of SARS-CoV infection, prophylactic and therapeutic remdesivir" exact="treatment" post="resulted in lower lung viral titers, and if therapy"/>
 <result pre="there were no differences in disease pathology or survival if" exact="treatment" post="was administered 2Â days post-infection. Some veterinary studies have"/>
 <result pre="signs and remained untreated [14]. In the 10 infected cats," exact="treatment" post="was initiated upon onset of FIP-associated clinical signs (~10â€&quot;18Â"/>
 <result pre="8Â months. All treated cats demonstrated favorable responses to GS-441524" exact="treatment" post="within 24â€&quot;48Â h, regardless of dose, and were still"/>
 <result pre="disease recurrence at 4Â weeks and 6Â weeks after initial" exact="treatment" post="and were re-treated. Adverse events related to treatment, other"/>
 <result pre="small number of animals, and it is unclear whether experimental" exact="infection" post="is a relevant representation of naturally-occurring FIPV infection in"/>
 <result pre="whether experimental infection is a relevant representation of naturally-occurring FIPV" exact="infection" post="in cats. Future studies with additional follow-up time would"/>
 <result pre="given the high fatality rate. In a field trial of" exact="treatment" post="with GS-441524 for naturally occurring FIP, Pedersen et al."/>
 <result pre="its prodrug remdesivir) is also a promising therapeutic candidate for" exact="treatment" post="of alphacoronavirus-related disease in cats. Most cats in this"/>
 <result pre="be drawn about whether remdesivir has greater efficacy in the" exact="treatment" post="of some clinical manifestations of FIP than others. A"/>
 <result pre="is that it was conducted among animals with naturally-occurring CoV" exact="infection" post="as a field trial, better representing real-world circumstances. 4.3"/>
 <result pre="In fact, there are many anecdotal reports already circulating about" exact="treatment" post="of COVID-19 patients with remdesivir. According to a recent"/>
 <result pre="after administration. Treatment was discontinued after respiratory symptoms improved (total" exact="treatment" post="durations of 4Â days, 5Â days, and 10Â days)."/>
 <result pre="treated with remdesivir for Ebola [39]. Incidentally, randomization to remdesivir" exact="treatment" post="was discontinued in this trial after an interim analysis"/>
 <result pre="authors hypothesized may be related to the fact that the" exact="treatment" post="plan for remdesivir involved multiple intravenous infusions. However, for"/>
 <result pre="induces severe adverse events in the patient. Alternatively, if the" exact="treatment" post="dose does not attain an effective serum concentration in"/>
 <result pre="clinical trials are underway on the use of remdesivir for" exact="treatment" post="of COVID-19 [41]. The NIH-sponsored clinical trial, ongoing in"/>
 <result pre="day, through discharge up to a maximum of 10 total" exact="treatment" post="days [20]. The primary outcome of the trial, as"/>
 <result pre="a seven-category clinical severity scale on the fifteenth day post" exact="treatment" post="initiation (Table 2) [42]. Additionally, Gilead Sciences is sponsoring"/>
 <result pre="will provide crucial information about whether remdesivir represents a viable" exact="treatment" post="option for COVID-19 [20,49]. If the trial findings are"/>
 <result pre="infectious peritonitis (FIP) virus in tissue culture and experimental cat" exact="infection" post="studiesVet. Microbiol.219201822623329778200 15ChoA.SaundersO.L.ButlerT.ZhangL.XuJ.VelaJ.E.Synthesis and antiviral activity of a series"/>
 <result pre="Lett.22820122705270722446091 16PedersenN.C.PerronM.BannaschM.MontgomeryE.MurakamiE.LiepnieksM.Efficacy and safety of the nucleoside analog GS-441524 for" exact="treatment" post="of cats with naturally occurring feline infectious peritonitisJ. Feline"/>
 <result pre="(2019-nCoV) in vitroCell Res.303202026927132020029 18de WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc. Natl."/>
 <result pre="Infect. Dis.31120009610010913403 30MorseJ.S.LalondeT.XuS.LiuW.R.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChembiochem.215202073073832022370"/>
</results>
